Otsuka (OTCMKTS:OTSKY) Sees Large Volume Increase – Here’s Why

Otsuka Holdings Co., Ltd. – Unsponsored ADR (OTCMKTS:OTSKY) shares saw an uptick in trading volume on Monday . 26,906 shares traded hands during mid-day trading, a decline of 31% from the previous session’s volume of 38,936 shares.The stock last traded at $34.10 and had previously closed at $32.97.

Wall Street Analyst Weigh In

Several brokerages have recently commented on OTSKY. Zacks Research raised Otsuka from a “strong sell” rating to a “hold” rating in a report on Tuesday, March 31st. The Goldman Sachs Group downgraded Otsuka from a “strong-buy” rating to a “strong sell” rating in a research report on Friday, February 27th. One equities research analyst has rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold”.

Otsuka Stock Performance

The stock has a market cap of $35.37 billion and a price-to-earnings ratio of 13.89. The company has a current ratio of 2.17, a quick ratio of 1.67 and a debt-to-equity ratio of 0.05. The firm has a fifty day simple moving average of $34.45 and a 200-day simple moving average of $32.47.

Otsuka (OTCMKTS:OTSKY) last announced its quarterly earnings data on Tuesday, April 28th. The company reported $0.59 EPS for the quarter, topping analysts’ consensus estimates of $0.43 by $0.16. Otsuka had a return on equity of 12.33% and a net margin of 15.01%.The firm had revenue of $3.96 billion during the quarter, compared to analyst estimates of $3.78 billion. Otsuka has set its FY 2026 guidance at 1.610-1.610 EPS. Analysts forecast that Otsuka Holdings Co., Ltd. – Unsponsored ADR will post 1.98 EPS for the current fiscal year.

Otsuka Company Profile

Otsuka Pharmaceutical Co, Ltd., trading in the U.S. under the ticker OTCMKTS:OTSKY, is a global healthcare company headquartered in Tokyo, Japan. The firm’s core activities span the development, manufacturing and marketing of prescription pharmaceuticals, consumer healthcare products and nutraceuticals. Otsuka focuses its research on areas such as neuroscience, cardiovascular and renal therapies, and oncology, aiming to bring innovative treatments to patients worldwide.

Founded in 1964 by Busaburo Otsuka as a subsidiary of the Otsuka Group, the company has grown into a diversified healthcare enterprise over more than five decades.